Drug Trial Radar · NCT06125951
Effect of 10 mg Xanamem on Dementia Due to Alzheimer's Disease
Last checked: Nov 20, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
247
Actual
Start
Apr 12, 2024
Primary completion
Sep 22, 2026
Study completion Feb 2028
Sponsor
- Lead sponsor
- Actinogen MedicalIndustry
- Sponsor type
- Industry
- First posted
- Nov 9, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Xanamem® is being developed as a potential treatment for symptomatic, early stages of Alzheimer's Disease (AD) and Major Depressive Disorder (MDD). This XanaMIA Phase 2b/3 study is to investigate the safety, tolerability, and efficacy of Xanamem in in mild or moderate dementia due to AD. Trial participants will be randomized to either receive 10mg of Xanamem once daily or a placebo for 36 weeks at a 1:1 ratio in a double-blinded fashion. Participants who have completed the main trial will be eligible to participate in an open-label phase, which involves treatment with 10mg Xanamem once daily for a treatment period of up to a maximum of 108 weeks. The OLE is intended to finish when all participants have completed at least 60 weeks of treatment and a follow-up visit 4 weeks later.
Conditions
- Dementia Moderate
- Dementia, Mild
- Alzheimer Disease
Interventions
XanamemDrug
Xanamem drug product is formulated as an immediate-release film-coated tablet formulation for oral administration. Each Xanamem tablet contains 10 mg Xanamem (UE2343) drug substance and excipients.
PlaceboDrug
Matching placebo which is identical in appearance to the test product (10 mg Xanamem once daily) except that it contains no active ingredient.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Effects of 10 mg Xanamem on integrated cognitive and functional abilitiesTime frame: 36 weeks
- Incidence and severity of treatment-emergent adverse events (TEAEs) [safety and tolerability of Xanamem]Time frame: 36 weeks
Locations
34 sites in 2 countries. Site status is shown where the registry gives one.
ACW Investigative Site 218
Carlsbad, California
ACW Investigative Site 209
Sherman Oaks, California
ACW Investigative Site 211
Denver, Colorado
ACW Investigative Site 208
Englewood, Colorado
ACW Investigative Site 203
Delray Beach, Florida
ACW Investigative site 201
Miami, Florida
ACW Investigative site 202
New Port Richey, Florida
ACW Investigative site 204
Orlando, Florida
ACW Investigative site 205
The Villages, Florida
ACW Investigative Site 207
Decatur, Georgia
ACW Investigative Site 206
Marlton, New Jersey
ACW Investigative Site 214
Albany, New York
ACW Investigative Site 219
Staten Island, New York
ACW Investigative Site 210
Dayton, Ohio
ACW Investigative Site 217
Independence, Ohio
ACW Investigative Site 212
Portland, Oregon
ACW Investigative Site 216
East Providence, Rhode Island
ACW Investigative Site 220
Austin, Texas
ACW Investigative Site 215
Bellevue, Washington
ACW Investigative Site 106
Darlinghurst, New South Wales, Australia
ACW Investigative Site 103
Erina, New South Wales, Australia
ACW Investigative Site 102
Kogarah, New South Wales, Australia
ACW Investigative Site 107
Macquarie Park, New South Wales, Australia
ACW Investigative Site 111
Newcastle, New South Wales, Australia
ACW Investigative Site 113
Birtinya, Queensland, Australia
ACW Investigative Site 105
Chermside, Queensland, Australia
ACW Investigative Site 114
Bedford Park, South Australia, Australia
ACW Investigative Site 110
Woodville South, South Australia, Australia
ACW Investigative Site 115
Carlton, Victoria, Australia
ACW Investigative Site 101
Ivanhoe, Victoria, Australia
ACW Investigative Site 108
Malvern, Victoria, Australia
ACW Investigative Site 112
Parkville, Victoria, Australia
ACW Investigative Site 104
Nedlands, Western Australia, Australia
ACW Investigative Site 109
West Perth, Western Australia, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.